Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo EFICAC-TTR: Exercício e Suplementação Nutricional na Amiloidose Cardíaca por Transtirretina (EFICAC-TTR)

22 de setembro de 2026 atualizado por: Universidad de Burgos

Um Estudo Clínico Prospectivo, Randomizado e Multicêntrico sobre o Efeito de um Programa de Exercício Multicomponente Domiciliário Combinado com Suplementação Nutricional em Doentes com Amiloidose Cardíaca por Transtirretina

Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life. Although disease-modifying treatments can slow cardiac disease progression, functional and nutritional impairment remain important unmet clinical needs.

EFICAC-TTR is a prospective, randomized, multicenter study designed to evaluate the effects of a 12-week home-based multicomponent exercise program combined with nutritional supplementation in adults aged 70 years or older with confirmed TTR-CA.

A total of 47 participants were randomized to one of three parallel groups: (1) usual medical care; (2) a home-based multicomponent exercise program plus microcrystalline cellulose control supplementation; or (3) the same exercise program plus creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

The primary functional outcomes are change in 6-minute walk test distance and handgrip strength from baseline to 12 weeks. Secondary outcomes include body composition, frailty, quality of life, and nutritional and clinical variables. Mechanistic biomarkers are assessed as exploratory outcomes.

The study aims to determine whether combining exercise with nutritional supplementation can improve functional capacity and related health outcomes in older adults with TTR-CA.

Visão geral do estudo

Descrição detalhada

Participants were randomized to three parallel study groups. The usual-care group continued standard clinical management without a structured exercise program or study supplementation. Participants in the two exercise groups performed the same 12-week home-based multicomponent exercise program adapted to individual functional capacity.

In addition to exercise, one group received daily microcrystalline cellulose as a control supplement, whereas the experimental group received creatine monohydrate (3 g/day) plus beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). The supplement comparison was blinded, while the comparison with usual care was necessarily open because of the behavioral intervention. Functional outcomes were assessed at baseline and after 12 weeks.

Biological samples collected at baseline and after the intervention are used for exploratory mechanistic analyses.

Tipo de estudo

Intervencional

Inscrição (Real)

47

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Castille and León
      • Aranda de Duero, Castille and León, Espanha
        • Hospital Santos Reyes
      • Burgos, Castille and León, Espanha, 09006
        • Hospital Universitario de Burgos
      • Soria, Castille and León, Espanha
        • Hospital Santa Bárbara

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

70 anos e mais velhos (Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ≥70 years.
  • Confirmed diagnosis of transthyretin cardiac amyloidosis (TTR-CA) based on positive bone scintigraphy with diphosphonates (Perugini grade 2 or 3) and absence of monoclonal protein.
  • Clinical stability during the 4 weeks prior to enrollment.
  • Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Light-chain (AL) amyloidosis or other non-TTR amyloidosis variants.
  • Absolute medical contraindication to moderate-intensity exercise.
  • Severe comorbid conditions with an estimated life expectancy <6 months.
  • Severe cognitive impairment (Mini-Mental State Examination score <20).
  • Concurrent participation in another clinical trial or structured exercise program.
  • Known allergy or intolerance to creatine, beta-hydroxy-beta-methylbutyrate (HMB), or microcrystalline cellulose.
  • Severe renal impairment requiring dialysis.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Usual Care

Participants received usual medical care for transthyretin cardiac amyloidosis, including routine cardiology follow-up and general lifestyle and nutritional recommendations, without the structured study exercise program or study supplementation.

Standard clinical management for transthyretin cardiac amyloidosis according to routine cardiology practice.

Comparador de Placebo: Exercise + Microcrystalline Cellulose Control Supplementation

Participants performed a 12-week home-based multicomponent exercise program and received daily microcrystalline cellulose as the control supplement. The supplement was provided in sachets matched to the supplementation procedure used in the experimental arm.

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with microcrystalline cellulose, used as a nutritionally inert control supplement to match supplementation procedures.

Experimental: Exercise + Creatine and HMB Supplementation

Participants performed the same 12-week home-based multicomponent exercise program and received daily supplementation with creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with creatine monohydrate (3 g/day) and β-hydroxy-β-methylbutyrate (HMB, 3 g/day) for 12 weeks.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Handgrip Strength
Prazo: Baseline and 12 weeks

Change in maximal isometric handgrip strength measured in kilograms (kg) using a calibrated handheld dynamometer (best of three attempts for the dominant hand), expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in 6-Minute Walk Test Distance
Prazo: Baseline and 12 weeks

Change in walking capacity assessed by the 6-minute walk test, measured as the difference in total distance walked (meters) between baseline and 12 weeks.

Baseline and 12 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Fat Mass
Prazo: Baseline and 12 weeks

Change in total body fat mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Skeletal Muscle Mass
Prazo: Baseline and 12 weeks

Change in skeletal muscle mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Fat-Free Mass
Prazo: Baseline and 12 weeks

Change in fat-free mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Phase Angle
Prazo: Baseline and 12 weeks

Change in phase angle measured in degrees (°) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Frailty Status Assessed by the FRAIL Scale
Prazo: Baseline and 12 weeks

Change in frailty status assessed by the FRAIL scale, a 5-item questionnaire with scores ranging from 0 to 5, where higher scores indicate greater frailty, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Short Physical Performance Battery (SPPB) Score
Prazo: Baseline and 12 weeks

Change in Short Physical Performance Battery (SPPB) total score, ranging from 0 to 12 points, where higher scores indicate better physical performance, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Clinical Frailty Scale (CFS) Score
Prazo: Baseline and 12 weeks

Change in frailty severity assessed by the Clinical Frailty Scale (CFS), a 9-point ordinal scale ranging from 1 (very fit) to 9 (terminally ill), where higher scores indicate greater frailty.

Baseline and 12 weeks
Change in Barthel Index Score
Prazo: Baseline and 12 weeks

Change in functional independence assessed by the Barthel Index, scored from 0 to 100, where higher scores indicate greater independence.

Baseline and 12 weeks
Change in SARC-F Score
Prazo: Baseline and 12 weeks

Change in sarcopenia risk assessed by the SARC-F questionnaire, with scores ranging from 0 to 10, where higher scores indicate greater sarcopenia risk.

Baseline and 12 weeks
Change in Minnesota Living With Heart Failure Questionnaire Score
Prazo: Baseline and 12 weeks

Change in health-related quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ), with total scores ranging from 0 to 105, where higher scores indicate worse quality of life.

Baseline and 12 weeks
Change in Charlson Comorbidity Index
Prazo: Baseline and 12 weeks

Change in comorbidity burden assessed using the Charlson Comorbidity Index, a weighted index that accounts for the number and severity of comorbid conditions, where higher scores indicate greater comorbidity burden.

Baseline and 12 weeks
Exercise Program Adherence
Prazo: Up to 12 weeks

Proportion (%) of prescribed exercise sessions completed, with adequate adherence defined as completion of at least 80% of prescribed sessions.

Up to 12 weeks
Supplement Adherence
Prazo: Up to 12 weeks

Proportion (%) of planned supplement doses consumed, with optimal compliance defined as 90-110%.

Up to 12 weeks
Change in Mini Nutritional Assessment Short-Form (MNA-SF) Score
Prazo: Baseline and 12 weeks

Change in nutritional status assessed by the Mini Nutritional Assessment Short-Form (MNA-SF), with scores ranging from 0 to 14 points, where lower scores indicate poorer nutritional status and greater risk of malnutrition.

Baseline and 12 weeks
Incidence of Intervention-Related Adverse Events
Prazo: Up to 12 weeks

Number and type of adverse events related to exercise and/or supplementation, classified according to severity and relatedness, collected during the 12-week intervention period.

Up to 12 weeks
Rate of Supplement Discontinuation
Prazo: Up to 12 weeks

Proportion of participants who discontinue study supplementation during the intervention period.

Up to 12 weeks
Change in Skeletal Muscle Index (SMI)
Prazo: Baseline and 12 weeks

Change in skeletal muscle index (SMI), expressed as skeletal muscle mass normalized to height squared (kg/m²), measured using multifrequency bioelectrical impedance analysis, between baseline and 12 weeks.

Baseline and 12 weeks

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change in Growth Differentiation Factor 15 (GDF-15)
Prazo: Baseline and 12 weeks

Change in serum GDF-15 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Soluble ST2
Prazo: Baseline and 12 weeks

Change in serum soluble ST2 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Interleukin-6 (IL-6)
Prazo: Baseline and 12 weeks

Change in serum interleukin-6 (IL-6) concentration (pg/mL) measured by immunoassay.

Baseline and 12 weeks
Change in C-Reactive Protein (CRP)
Prazo: Baseline and 12 weeks

Change in serum C-reactive protein (CRP) concentration (mg/dL) measured by immunoassay.

Baseline and 12 weeks
Change in circulating miR-21 expression
Prazo: Baseline and 12 weeks

Change in circulating miR-21 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-29 expression
Prazo: Baseline and 12 weeks

Change in circulating miR-29 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-34a expression
Prazo: Baseline and 12 weeks

Change in circulating miR-34a expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-155 expression
Prazo: Baseline and 12 weeks

Change in circulating miR-155 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in PBMC Immune Polarization Profile by Flow Cytometry
Prazo: Baseline and 12 weeks

Change in the immunophenotypic profile of peripheral blood mononuclear cells (PBMCs) assessed by multiparametric flow cytometry, including the relative abundance of cell populations with M1-like and M2-like phenotypes and their ratio.

Baseline and 12 weeks
Change in Pro-inflammatory (M1) Gene Expression Markers
Prazo: Baseline and 12 weeks

Change in gene expression of predefined pro-inflammatory (M1-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Anti-inflammatory (M2) Gene Expression Markers
Prazo: Baseline and 12 weeks

Change in gene expression of predefined anti-inflammatory/regenerative (M2-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Serum Albumin
Prazo: Baseline and 12 weeks

Change in serum albumin concentration (g/dL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Serum Prealbumin
Prazo: Baseline and 12 weeks

Change in serum prealbumin concentration (g/dL) between baseline and 12 weeks

Baseline and 12 weeks
Change in Vitamin D
Prazo: Baseline and 12 weeks

Change in serum 25-hydroxyvitamin D concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Galectin-3
Prazo: Baseline and 12 weeks

Change in serum galectin-3 concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in NT-proBNP
Prazo: Baseline and 12 weeks

Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in High-Sensitivity Troponin T
Prazo: Baseline and 12 weeks

Change in serum high-sensitivity cardiac troponin T concentration (ng/L) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Leptin
Prazo: Baseline and 12 weeks

Change in serum leptin concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Adiponectin
Prazo: Baseline and 12 weeks

Change in serum adiponectin concentration (µg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in IGF-1
Prazo: Baseline and 12 weeks

Change in serum insulin-like growth factor 1 (IGF-1) concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Klotho
Prazo: Baseline and 12 weeks

Change in serum Klotho concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Juan Mielgo-Ayuso, PhD, Universidad de Burgos
  • Investigador principal: José A Pérez Rivera, PhD, MD, Hospital Universitario de Burgos

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de fevereiro de 2026

Conclusão Primária (Real)

10 de setembro de 2026

Conclusão do estudo (Real)

10 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

17 de dezembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de janeiro de 2026

Primeira postagem (Real)

15 de janeiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request.

Prazo de Compartilhamento de IPD

Beginning 6 months after publication and ending 5 years after publication.

Critérios de acesso de compartilhamento IPD

Access to de-identified individual participant data will be granted upon reasonable request to the principal investigator. Requests must include a methodologically sound research proposal and will be evaluated for scientific merit and feasibility. Data sharing will require the execution of a data sharing agreement and will comply with applicable data protection and privacy regulations.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever